Logo

Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China

Share this

Biotheus Enters into an Agreement with Alligator Bioscience to Develop Bispecific Molecules in Greater China

Shots:

  • Alligator to receive ~52M in development milestones including $1M up front- $90M as option fee and royalties on sales and share of sub-license revenue. Biotheus to get right to an antibody from ALLIGATOR-GOLD to develop up to three bispecific molecules in Greater China with an option to expand the license for global rights
  • The agreement provides entrance to the Alligator’s antibody library in China and proven its expertise in developing antibodies against TNFR family members
  • ALLIGATOR-GOLD is a human Ab library containing 60B+ unique antibody fragments and has five leading clinical and preclinical drug candidates including ADC-1013- ATOR-1015- ATOR-1017- ALG.APV-527 and ATOR-1144

Click here to­ read full press release/ article | Ref: PRnewswire| Image: Camegie


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions